Human Rabies Immunoglobulin Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 150 IU,300IU

Reference Brands: HyperRAB (USA), Berirab P (EU), Rabigam (India), Kedrab (USA)

Category: Vaccines

Human Rabies Immunoglobulin is used with rabies vaccine to prevent Rabies. It works by giving your body the antibodies it needs to protect against the rabies virus. It is administered only once, at the beginning of anti-rabies prophylaxis, to previously unvaccinated persons. HUMAN RABIES IMMUNOGLOBULIN is available in Injection and strengths such as 150 IU,300IU. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, HUMAN RABIES IMMUNOGLOBULIN is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

HUMAN RABIES IMMUNOGLOBULIN can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Human Rabies Immunoglobulin (HRIG) is a plasma-derived biological product used for post-exposure prophylaxis (PEP) in individuals exposed to the rabies virus through animal bites or scratches. It provides immediate passive immunity by supplying rabies virus–neutralizing antibodies directly at the site of exposure. This protection is crucial during the early phase of treatment until the body develops its own active immune response following rabies vaccination. HRIG is recommended particularly for category III exposures, which include severe bites, scratches, or contamination of mucous membranes with saliva from potentially rabid animals.

The immunoglobulin is derived from human plasma collected from donors with high levels of rabies antibodies and is purified to ensure safety and efficacy. It is typically administered once at the beginning of rabies post-exposure prophylaxis, with as much of the calculated dose as possible infiltrated around the wound site and the remainder given intramuscularly. When used together with a full course of rabies vaccine and proper wound management, HRIG significantly reduces the risk of rabies infection. Its role in providing rapid protection makes it an essential component of modern rabies prevention protocols worldwide.